Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q1 2024 Earnings Presentation
14 slides from Pacira Biosciences's earnings presentation, May 7, 2024
Slide 1: 1Q24 Earnings Presentation
1Q24 Earnings Presentation May 2024
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, wi
Slide 3: Advancing three key EXPAREL drivers in 2024
Advancing three key EXPAREL drivers in 2024 Advancing the Awareness and Expanding access launch of EXPAREL educational through 340B in two new lower initiatives for pricing and new extremity nerve separate outpatient GPO partnerships block indications reimbursement beginning in 2025 3
Slide 4: Lower extremity nerve block launch receiving positive market receptivity across all sites of care
Lower extremity nerve block launch receiving positive market receptivity across all sites of care • Attractive value proposition; 4 days of opioid- EXPAREL is sparing pain control with single 10 mL dose • Extends reach within surgeries of the knee, lower leg, for use in lower extremity and foot and
Slide 5: Separate CMS EXPAREL reimbursement across all outpatient settings marks an important milestone
Separate CMS EXPAREL reimbursement across all outpatient settings marks an important milestone Flaws of bundled payments Patient-centric legislative Opportunity to greatly for surgical procedures solution expand patient access • Impedes patient and provider • NOPAIN signed into law in Reimbursement
Slide 6: Advancing pre-launch activities to maximize reimbursement opportunity
Advancing pre-launch activities to maximize reimbursement opportunity Enhancing commercial organization to ensure operational excellence across Marketing Strategic Accounts Medical & Market Access AWARENESS EDUCATION ACTION Pharmacy C-suite Clinicians Payers Influencers Patients 6
Slide 7: Paving the way for separate EXPAREL reimbursement
Paving the way for separate EXPAREL reimbursement • Launching new GPO partnerships in 2024 ~25% of EXPAREL-relevant market procedures are in – In 1Q24, announced deal with Premier whose network of hospitals and health systems covers ~20% of EXPAREL-relevant market procedures inpatient 2 additional G
Slide 8: PCRX-201 has the potential to be an important disease-modifying gene therapy for knee OA
PCRX-201 has the potential to be an important disease-modifying gene therapy for osteoarthritis (OA) of the knee • Novel, Helper-Dependent Adenovirus • 52-week Phase 1 data presented at (HDAd) vector gene therapy product OARSI 2024 – a single IA injection: candidate for knee OA – Sustained clinical
Slide 9: High need for novel OA of the knee treatments given lack of durable efficacy
High need for novel OA of the knee treatments given lack of durable efficacy in current therapies 14M Americans suffer from symptomatic knee OA +12 TRANSFORMATIVE MONTHS DURABILITY considered First-ever FDA RMAT 2M younger than 45 designated gene therapy product in OA Favorable Cost of Goods Profile
Slide 10: Strong first quarter financial performance
Strong first quarter financial performance • 1Q24 total revenue of $167M 2024 Financial Guidance Reiterated as of 1Q24 Total Revenue $680-705M – EXPAREL net product sales of $132M Non-GAAP Gross Margin 74-76% – ZILRETTA net product sales of $26M Non-GAAP R&D $70-80M – iovera° net product sales of $5
Slide 11: Positioned for sustainable success
Positioned for sustainable success Sharply focused on driving long-term growth 3 best-in-class products LENB launch receiving positive market receptivity Significant reimbursement opportunity ahead 2024 a key setup year to drive growth in 2025 and beyond Advancing an important gene therapy in OA 11
Slide 12: Appendix
APPENDIX BIOSCIENCES , INC
Slide 13: Non-GAAP disclosure
Non-GAAP disclosure Pacira BioSciences, Inc. Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (Non-GAAP) (in thousands) (unaudited) Three Months Ended March 31, 2024 GAAP net income (loss) $ 8,979 Interest income (3,903) Interest expense (1) 3,316 Income tax expense (benefit) 4,661 Deprec
Slide 14: Thank you
BIOSCIENCES , INC